ANDA 207289, held by Amneal Pharms. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 207289 (Doxycycline Hyclate), held by Amneal Pharms, was first approved by FDA on Jun 27, 2016, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 27, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE · capsule;oral | Doxycycline Hyclate | Rx |
| Aug 11, 2026 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jun 24, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jul 25, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 5, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 5, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 5, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 27, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters